Fabrizio Pane

1979–2025 年に発表

120
論文数
18,614
被引用数
64
h 指数
111
i10 指数

被引用数

Fabrizio Pane の年別被引用数1979 年: 被引用 9 件1996 年: 被引用 3 件1997 年: 被引用 5 件1998 年: 被引用 2 件1999 年: 被引用 17 件2000 年: 被引用 8 件2001 年: 被引用 16 件2002 年: 被引用 24 件2003 年: 被引用 28 件2004 年: 被引用 31 件2005 年: 被引用 32 件2006 年: 被引用 43 件2007 年: 被引用 64 件2008 年: 被引用 60 件2009 年: 被引用 103 件2010 年: 被引用 107 件2011 年: 被引用 126 件2012 年: 被引用 119 件2013 年: 被引用 115 件2014 年: 被引用 117 件2015 年: 被引用 159 件2016 年: 被引用 145 件2017 年: 被引用 112 件2018 年: 被引用 98 件2019 年: 被引用 392 件2020 年: 被引用 494 件2021 年: 被引用 534 件2022 年: 被引用 387 件2023 年: 被引用 256 件2024 年: 被引用 481 件2025 年: 被引用 171 件2026 年: 被引用 3 件1980〜1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,196 件、この内訳の 18.8%イタリア: 引用元論文 723 件、この内訳の 11.4%ドイツ: 引用元論文 524 件、この内訳の 8.3%イギリス: 引用元論文 459 件、この内訳の 7.2%フランス: 引用元論文 396 件、この内訳の 6.2%中国: 引用元論文 243 件、この内訳の 3.8%スペイン: 引用元論文 223 件、この内訳の 3.5%オランダ: 引用元論文 189 件、この内訳の 3%オーストラリア: 引用元論文 182 件、この内訳の 2.9%スイス: 引用元論文 180 件、この内訳の 2.8%カナダ: 引用元論文 162 件、この内訳の 2.6%日本: 引用元論文 130 件、この内訳の 2.1%
0%18.8%その他 27.4%

分野

  • Medicine85.4%
  • Biochemistry, Genetics and Molecular Biology8.8%
  • Immunology and Microbiology3.7%
  • Computer Science0.6%
  • Neuroscience0.3%
  • Chemistry0.2%
  • その他1%

トピック

  • Chronic Myeloid Leukemia Treatments14.7%
  • Acute Myeloid Leukemia Research8.9%
  • Chronic Lymphocytic Leukemia Research7.5%
  • Eosinophilic Disorders and Syndromes7.5%
  • Acute Lymphoblastic Leukemia research5.8%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment5.6%
  • その他50%

共著者

全論文

検索で開く
  1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann - Leukemia 2020 被引用: 1,510

  2. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

    著者: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 872

  3. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John M. Goldman, Rüdiger Hehlmann - Blood 2013 被引用: 1,989

  4. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

    著者: , , , , , , , , , , , , , , , , , , , - Leukemia 2003 被引用: 1,528

  5. Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Attilio Olivieri, Shahram Kordasti, Francesco Albano, Fabrizio Pane, Pellegrino Musto, Monica Bocchia, Elisabetta Lugli, Massimo Breccia, Marco Frigeni, Lorenzo Dagna, Raffaella Greco, Franco Franceschini, Corrado Campochiaro, Luca Cantarini, Maria Teresa Voso - American Journal of Hematology 2023 被引用: 44

  6. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making

    著者: , , , , , , , , - Leukemia 2013 被引用: 169

  7. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patrizia Tosi, Francesco Lanza, Massimo Massaia, Mauro Turrini, Felicetto Ferrara, Carmela Gurrieri, Daniele Vallisa, Maurizio Martelli, Enrico Derenzini, Attilio Guarini, Annarita Conconi, Annarosa Cuccaro, Laura Cudillo, Domenico Russo, Fabrizio Ciambelli, Anna Maria Scattolin, Mario Luppi, Carmine Selleri, Elettra Ortu La Barbera, Celestino Ferrandina, Nicola Di Renzo, Attilio Olivieri, Monica Bocchia, Massimo Gentile, Francesco Marchesi, Pellegrino Musto, Augusto B. Federici, Anna Candoni, Adriano Venditti, Carmen Fava, Antonio Pinto, Piero Galieni, Luigi Rigacci, Daniele Armiento, Fabrizio Pane, Margherita Oberti, Patrizia Zappasodi, Carlo Visco, Matteo Franchi, Paolo Grossi, Lorenza Bertù, Giovanni Corrao, Livio Pagano, Paolo Corradini - The Lancet Haematology 2020 被引用: 554

  8. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi - NEJM Evidence 2023 被引用: 51

  9. IKZF1 (Ikaros) Deletions in BCR-ABL1 –Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 被引用: 322

  10. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi - The Lancet Haematology 2021 被引用: 132

  11. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 被引用: 1,298

  12. Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tomas G. Neilan, Joerg Herrmann, Amam Mbakwem, Mariana Mirabel, Hadi Skouri, Emilio Hirsch, Alain Cohen‐Solal, Aaron L. Sverdlov, Peter van der Meer, Riccardo Asteggiano, Ana Barac, Bonnie Ky, Daniel J. Lenihan, Susan Dent, Petar Seferović, Andrew J.S. Coats, Marco Metra, Giuseppe Rosano, Thomas Suter, Teresa López‐Fernández, Alexander R. Lyon - European Journal of Heart Failure 2024 被引用: 68

  13. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gianpietro Semenzato, Roberto M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Daniela Bartoletti, Simona Paglia, Nicola Vianelli, Michèle Cavo, Massimiliano Bonifacio, Giuseppe A. Palumbo - Cancer 2023 被引用: 40

  14. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

    著者: , , , , , , , , , , , , , , - Leukemia & lymphoma/Leukemia and lymphoma 2019 被引用: 150

  15. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roberto M. Lemoli, Alessandra Iurlo, Nicola Vianelli, Michèle Cavo, Massimo Breccia, Massimiliano Bonifacio - Blood Cancer Journal 2021 被引用: 75

  16. Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2023 被引用: 27

  17. New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia

    著者: , , , , , , , , , , , , , , - Current Research in Translational Medicine 2023 被引用: 23

  18. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

    著者: , , , , , , , , , , , , , - Blood 2011 被引用: 579

  19. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

    著者: , , , , , , , , , , - mAbs 2013 被引用: 154

  20. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2020 被引用: 142

  21. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

    著者: , , , , , , , , , , , , , , , , , , , , - Leukemia 2015 被引用: 342

  22. Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma

    著者: , , , , , , , , - Journal of Nuclear Medicine 2012 被引用: 185

  23. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michèle Cavo, Giovanni Martinelli - Blood 2019 被引用: 99

  24. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesco Cavazzini, Nicola Sgherza, Valentina Giai, Luigia Luciano, Sabina Russo, Pellegrino Musto, Giovanni Caocci, Federica Sorà, Francesco Iuliano, Francesca Lunghi, Giorgina Specchia, Fabrizio Pane, Dario Ferrero, Michele Baccarani, Giuseppe Saglio - Haematologica 2019 被引用: 77